News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Chemizon Inc. Collaborates with Korean Research Institute


2/14/2008 10:06:34 AM

February 13, 2008 -- Chemizon, a drug discovery CRO based in the US but with labs in Seoul and Beijing, will collaborate with the Korean Research Institute of Bioscience and Biotechnology (KRIBB) to commercialize KRIBB’s IP. To do this, the two entities will spin out a new biotech company. Chemizon said that its new Chemizon-Oakwood Bioventures private equity fund will be the lead investor in the new KRIBB company, currently given the working name “NuCo.” Chemizon-Oakwood Bioventures will build a management team and incubate the company. At the same time, Chemizon will use its integrated drug discovery platform to help convert KRIBB’s discoveries into small molecule therapeutics.

Read at ChinaBio Today

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES